PHARM—An interactive graphic program for individual and population pharmacokinetic parameter estimation

Goméni, Roberto

doi:10.1016/0010-4825(84)90017-9

Cited by 142 publications

(55 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The baseline value was subtracted from the measured concentration and a poly-exponential equation was fitted to the concentration-time data by the non-linear regression program Siphar (Gomeni, 1984) using weighted least squares (weight = 1/y) analysis. The chosen model was used to characterize the absorption and to determine the terminal elimination halflife.…”

Section: Pharmacokinetic Analysismentioning

confidence: 99%

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Salmonson

Danielson

Wíkström

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The pharmacokinetics of recombinant erythropoietin, r-Epo, were evaluated after intravenous and subcutaneous administration of 50 u kg-' to six healthy male volunteers. 2 The calculated mean values (± s.d.) for volume of distribution at steady state and clearance after an i.v. dose were 76 (±33) ml kg-l and 12 (±3) ml h'-kg-l, respectively. 3 Serum concentrations of r-Epo peaked at 13 (±6) h after the s.c. dose and the bioavailability over 72 h was 36 (±23)%. The mean residence time and half-life of erythropoietin were 6.2 (± 1.0) and 4.5 (±0.9) h respectively after i.v. and 46 (± 18) and 25 (± 12) h after s.c. administration. 4 The results demonstrate the possibility of changing the profile of the concentrationtime curve by changing the mode of administration of r-Epo, with implications for the time-course of clinical response.

show abstract

Section: Pharmacokinetic Analysismentioning

confidence: 99%

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Salmonson

Danielson

Wíkström

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The goodness-of-fit of computed to observed data was based on visual inspection, coefficient of correlation, residual plots, standard deviation of estimated parameters, correlation matrix and Akaike's information criteria. Data analysis was performed using the computer program SIPHAR (Gomeni, 1984), which has been validated against SAS (release 5.16), BMDP and NONLIN.…”

Section: Introduction Variability Methodsmentioning

confidence: 99%

Inter‐ and intraindividual variability in the concentration‐effect (sedation) relationship of flunitrazepam.

Grahnén¹,

Wennerlund²,

Dahlström³

et al. 1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…After 2 h, the subjects had a light breakfast and were allowed to drink freely. Venous blood was sampled via an indwelling intravenous heparin lock catheter at 0, 30, 45, 60, and 90 min and 2, 3,4,6,7,8,12, and 26 h postdosing. Inflammatory exudate from the blisters was collected with a micropipette at 30 min and 1, 2, 3, 4, 6, 8, 12, and 26 h. The blisters were resealed by spraying with a fast-drying plastic Nobecutane dressing (Astra Pharmaceuticals Ltd., King's Langley, United Kingdom).…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers

O’Neill

Nye

Douce

et al. 1990

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The pharmacokinetics of cefpodoxime were determined after a single oral dose of 261 mg of cefpodoxime proxetil, equivalent to 200 mg of cefpodoxime, was given to each of six healthy male volunteers. Concentrations in serum, urine, and cantharidin-induced inflammatory fluid were measured by a microbiological assay. The mean peak level in plasma was 2.1 micrograms/ml, attained at a mean time of 2.9 h. The mean half-life of elimination from serum was 2.2 h. The inflammatory exudate was penetrated moderately rapidly, the mean peak level being 1.7 micrograms/ml at 3.5 h. The mean percent penetration of the inflammatory exudate was 103.7. The mean 24-h urine recovery of cefpodoxime was 32.2%. This study suggests that cefpodoxime proxetil taken once or twice daily will be sufficient to treat urinary or systemic infections caused by susceptible pathogens.

show abstract

PHARM—An interactive graphic program for individual and population pharmacokinetic parameter estimation

Cited by 142 publications

References 12 publications

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Inter‐ and intraindividual variability in the concentration‐effect (sedation) relationship of flunitrazepam.

Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers

Contact Info

Product

Resources

About